Using bioinformatic research tools, it was shown that CD96 expression was lower in rectal cancer, melanoma, and fibrosarcoma compared to paraneoplastic tissue, which implies that CD96 could promote CD8+ T cell activation as a co-stimulatory receptor. This evidence concerns the gene CD96 and melanoma.